CSL Ltd Annual Report 2019

Support for biomedical communities To help advance scientific knowledge in areas of unmet patient need, CSL engages in direct collaborations with medical research institutes and universities. We also offer research grants to institutes, hospitals and patient organisations. Additionally, CSL funds investigator- initiated studies (IIS), projects undertaken by researchers outside CSL’s research and development (R&D) activities to better understand the potential use of its products to treat new indications or therapy areas. For an IIS, CSL does not have any role in the conduct of the study and does not claim exclusivity over research outcomes, but does provide support through the provision of product and/or financial grants. In 2018/19, there were 42 studies in operation, spanning a multitude of areas including acquired bleeding, reversal of oral anticoagulants, haemophilia A and B, von Willebrand disease, antibody-mediated rejection after transplantation, immunodeficiency, chronic inflammatory demyelinating polyneuropathy, alpha 1 antitrypsin deficiency and hereditary angioedema. At CSL, we are committed to supporting established researchers and the researchers of tomorrow – the scientists whose discoveries will help patients lead longer, fuller lives. The CSL Centenary Fellowships are competitively selected, high-value grants available to mid-career Australians who wish to continue medical research in Australia. Two individual, five-year, A$1.25 million fellowships are awarded each year. The 2019 CSL Centenary Fellowships were awarded to Dr Connie Wong fromMonash University and Dr Daniel Pellicci from the Murdoch Children’s Research Institute. Dr Wong is using her Fellowship to understand why as many as one-fifth of deaths following stroke are caused by pneumonia and other infections. Dr Pellicci is using his Researchers at academic and research institutions throughout the region were invited to submit proposals for projects with a focus on therapeutics that fit within CSL Behring’s areas of expertise, including inflammatory and autoimmune diseases; haematological and coagulation disorders; transplantation; cardiovascular and metabolic diseases; respiratory diseases; and neurological disorders. Through the agreement, the Science Center’s framework for technology commercialisation and network of research and academic partners will provide the support and infrastructure for CSL Behring to efficiently evaluate promising technologies frommultiple institutions. CSL Behring’s operational headquarters is located near Philadelphia in King of Prussia, Pennsylvania, US. In 2019/20, two US$250,000 CSL Behring grants will be awarded to researchers, with the recipients also afforded the opportunity to work alongside CSL experts to help transform their ideas into groundbreaking therapies to improve patients' health. 2019 CSL Centenary Fellowship recipients Progress through strategic partnerships In October, CSL Behring and the University City Science Center in Philadelphia joined forces to identify promising technologies and support the commercialisation pathways of potential new discoveries. Fellowship to focus on people suffering from tuberculosis. He hopes his work will lead the way to an improved vaccine plus other new immune therapies. In Europe, Seqirus has established a €50,000 research grant annually for three years, for a Fellowship through the European Society for Paediatric Infectious Diseases. This will be awarded to researchers specialising in paediatric patients, whose immune systems are considered “immature” and who are therefore at increased risk of developing severe influenza. CSL Limited Annual Report 2019 39